Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Antimicrobial peptides stage a comeback

A Correction to this article was published on 01 December 2013

This article has been updated

Better understanding of the mechanisms of action, modification and synthesis of antimicrobial peptides is reigniting commercial development. Jeffrey L. Fox reports.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Antimicrobial peptides take shape.

Change history

  • 27 June 2013

    In the version of this article initially published, the Italian company researching the use of novel antibiotics was erroneously identified as NeED Pharmaceuticals. The company’s name is NAICONS.

  • 01 December 2013

    In the May 2013 news analysis “Antimicrobials stage a comeback” (Nat. Biotechnol. 31, 379–382, 2013), the Italian company researching the use of novel antibiotics was erroneously identified as NeED Pharmaceuticals. The company's name is NAICONS. The error has been corrected in the PDF and HTML versions of this article.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fox, J. Antimicrobial peptides stage a comeback. Nat Biotechnol 31, 379–382 (2013). https://doi.org/10.1038/nbt.2572

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2572

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing